January 05, 2023
Based on findings from a phase 1 study, the FDA has received a biologics license application for cosibelimab for patients with advanced or metastatic cutaneous squamous cell carcinoma.
November 29, 2022
During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.
November 20, 2022
Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.
November 16, 2022
In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.
November 10, 2022
During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.
October 21, 2022
In patients with completely resected stage IIB or IIC melanoma, use of adjuvant nivolumab achieved a 58% reduction in the risk of recurrence or death.
October 19, 2022
Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
October 17, 2022
Glenn J. Hanna, MD, discusses the results of a study investigating nivolumab as treatment for proliferative leukoplakia leading to oral cancer.
October 12, 2022
Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
October 11, 2022
Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.